MP010 / Medpacto - LARVOL DELTA

MedPacto announced on the 19th that its novel immuno-oncology treatment, “MP010,“ has been selected as a new project for support in the 2nd National New Drug Development Project for 2025, hosted by the National Drug Development Fund. [Google translation] (Hankyung) - "In animal experiments, MedPacto has confirmed a high complete remission (CR) rate, long-term survival rate, and immune memory effect in refractory cancers such as pancreatic cancer and triple-negative breast cancer with only 'MP010' administered as a single agent. With this project selection, MedPacto plans to obtain approval for the investigational new drug (IND) plan for 'MP010' and begin early clinical development in earnest."

Financing • Preclinical • Pancreatic Cancer • Triple Negative Breast Cancer